Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 255,272 shares, an increase of 675.7% from the August 15th total of 32,907 shares. Approximately 1.9% of the shares of the stock are short sold. Based on an average trading volume of 674,900 shares, the short-interest ratio is currently 0.4 days.

Biofrontera Price Performance

BFRI stock traded up $0.09 during midday trading on Friday, reaching $1.55. The company had a trading volume of 1,439,805 shares, compared to its average volume of 683,767. The firm has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.07. The company has a market capitalization of $23.02 million, a P/E ratio of -3.44 and a beta of 0.83. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. On average, research analysts anticipate that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its position in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. Institutional investors own 10.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on BFRI shares. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen upgraded shares of Biofrontera from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.